» Articles » PMID: 25299073

MiR-181b-5p Downregulates NOVA1 to Suppress Proliferation, Migration and Invasion and Promote Apoptosis in Astrocytoma

Overview
Journal PLoS One
Date 2014 Oct 10
PMID 25299073
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are small, short noncoding RNAs that modulate the expression of numerous genes by targeting their mRNA. Numerous abnormal miRNA expression patterns are observed in various human malignancies, and certain miRNAs can act as oncogenes or tumor suppressors. Astrocytoma, the most common neuroepithelial cancer, represents the majority of malignant brain tumors in humans. In our previous studies, we found that the downregulation of miR-181b-5p in astrocytomas is associated with a poor prognosis. The aim of the present study was to investigate the functional role of miR-181b-5p and its possible target genes. miR-181b-5p was significantly downregulated in astrocytoma specimens, and the reduced expression of miR-181b-5p was inversely correlated with the clinical stage. The ectopic expression of miR-181b-5p inhibited proliferation, migration and invasion and induced apoptosis in astrocytoma cancer cells in vitro. The NOVA1 (neuro-oncological ventral antigen 1) gene was further identified as a novel direct target of miR-181b-5p. Specifically, miR-181b-5p bound directly to the 3'-untranslated region (UTR) of NOVA1 and suppressed its expression. In clinical specimens, NOVA1 was overexpressed, and its protein levels were inversely correlated with miR-181b-5p expression. Furthermore, the changing level of NOVA1 was significantly associated with a poor survival outcome. Similar to restoring miR-181b-5p expression, downregulating NOVA1 inhibited cell growth, migration and invasion. Overexpression of NOVA1 reversed the inhibitory effects of miR-181b-5p. Our results indicate that miR-181b-5p is a tumor suppressor in astrocytoma that inhibits tumor progression by targeting NOVA1. These findings suggest that miR-181b-5p may serve as a novel therapeutic target for astrocytoma.

Citing Articles

The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer.

Herman-Sanchez N, G-Garcia M, Jimenez-Vacas J, Yubero-Serrano E, Lopez-Sanchez L, Romero-Martin S Cell Mol Life Sci. 2024; 82(1):18.

PMID: 39725737 PMC: 11671448. DOI: 10.1007/s00018-024-05515-6.


NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.

Zeng S, Jiang K, Ge J, Tang M, Wen Y, Ma X BMC Cancer. 2024; 24(1):1502.

PMID: 39639242 PMC: 11619257. DOI: 10.1186/s12885-024-13271-w.


Correction: MiR-181b-5p Downregulates NOVA1 to Suppress Proliferation, Migration and Invasion and Promote Apoptosis in Astrocytoma.

Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue L PLoS One. 2024; 19(7):e0306667.

PMID: 38950023 PMC: 11216568. DOI: 10.1371/journal.pone.0306667.


Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery.

Blazquez-Encinas R, Garcia-Vioque V, Caro-Cuenca T, Moreno-Montilla M, Mangili F, Alors-Perez E J Transl Med. 2023; 21(1):879.

PMID: 38049848 PMC: 10696873. DOI: 10.1186/s12967-023-04754-8.


The role of alternative pre-mRNA splicing in cancer progression.

Choi S, Cho N, Kim E, Kim K Cancer Cell Int. 2023; 23(1):249.

PMID: 37875914 PMC: 10594706. DOI: 10.1186/s12935-023-03094-3.


References
1.
Ruggiu M, Herbst R, Kim N, Jevsek M, Fak J, Mann M . Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing. Proc Natl Acad Sci U S A. 2009; 106(9):3513-8. PMC: 2642475. DOI: 10.1073/pnas.0813112106. View

2.
Zhang C, Frias M, Mele A, Ruggiu M, Eom T, Marney C . Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. Science. 2010; 329(5990):439-43. PMC: 3412410. DOI: 10.1126/science.1191150. View

3.
Park E, Iaccarino C, Lee J, Kwon I, Baik S, Kim M . Regulatory roles of heterogeneous nuclear ribonucleoprotein M and Nova-1 protein in alternative splicing of dopamine D2 receptor pre-mRNA. J Biol Chem. 2011; 286(28):25301-8. PMC: 3137101. DOI: 10.1074/jbc.M110.206540. View

4.
Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B . An RNA map predicting Nova-dependent splicing regulation. Nature. 2006; 444(7119):580-6. DOI: 10.1038/nature05304. View

5.
Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View